Immunocore Holdings plc (IMCR)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 30 | 27 | 144 | 197 | 248 | 298 | 404 | 452 |
| Operating profit | $m | -34 | -17 | ||||||
| Net profit | $m | -74 | -133 | -43 | -44 | -41 | -26 | -9 | -3 |
| EPS reported | $ | -0.53 | -0.19 | ||||||
| Operating cashflow per share | $ | -0.16 | -1.11 | ||||||
| Capex per share | $ | 0.06 | 0.12 | ||||||
| FCF per share | $ | -0.22 | -1.23 | ||||||
| Free cash flow | $m | -11 | -63 | ||||||
| Net debt | $m | -471 | -486 | ||||||
| Book value equity | $m | 381 | 420 | ||||||
| Book value per share | $ | 7.57 | 8.24 | ||||||
| Number of shares | m | 50.35 | 50.97 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 4.59 | 4.16 | ||||||
| P/S LTM | x | 5.87 | 4.33 | ||||||
| P/FCF LTM | x | -156.07 | -27.95 | ||||||
| EV/EBITDA LTM | x | 4,433.31 | 105.87 | ||||||
| EV/Sales LTM | x | 5.77 | 4.18 | ||||||
| Earnings Yield LTM | % | -1.51% | -0.53% | ||||||
| FCF Yield | % | -0.64% | -3.58% | ||||||
| Quality | |||||||||
| ROE | % | -6.93% | -2.35% | ||||||
| ROIC | % | -4.10% | +13.56% | ||||||
| Operating margin | % | -11.34% | -4.33% | ||||||
| Gross margin | % | +97.91% | +98.85% | ||||||
| FCF/Sales | % | -3.76% | -15.49% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +20.00% | +62.80% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.03 | -0.14 | ||||||
| Net Debt/EBITDA | x | -80.12 | -3.08 | ||||||
| EBIT/Net interest | x | -2.77 | -1.52 | ||||||
| Net debt/market cap | % | +22.50% | +22.67% | ||||||
| Net debt/Equity | x | -1.24 | -1.16 | ||||||
| Gross debt/equity | x | 1.15 | 1.04 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized. Within oncology, Immunocore is progressing IMC-C103C through early-stage (Phase I/II) dose escalation trials for several solid tumor types, notably non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers. Another key oncology program, IMC-F106C, is also in Phase I/II dose escalation studies for a diverse array of solid malignancies, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. For infectious diseases, the company is advancing IMC-I109V in Phase I/II clinical trials for chronic hepatitis B virus, alongside IMC-M113V, which is undergoing preclinical development for human immunodeficiency virus (HIV). Additionally, Immunocore is developing novel therapeutic candidates designed to deliver precise, targeted immunosuppression as a treatment strategy for autoimmune conditions.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized. Within oncology, Immunocore is progressing IMC-C103C through early-stage (Phase I/II) dose escalation trials for several solid tumor types, notably non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers. Another key oncology program, IMC-F106C, is also in Phase I/II dose escalation studies for a diverse array of solid malignancies, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. For infectious diseases, the company is advancing IMC-I109V in Phase I/II clinical trials for chronic hepatitis B virus, alongside IMC-M113V, which is undergoing preclinical development for human immunodeficiency virus (HIV). Additionally, Immunocore is developing novel therapeutic candidates designed to deliver precise, targeted immunosuppression as a treatment strategy for autoimmune conditions.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free